Efficacy and safety of TDF+3TC + EFV‑centric antiretroviral regimens for HIV/HBV co-infection: a systematic review and network meta‑analysis
BMC Infectious Diseases·
- DOI
- 10.1186/s12879-026-13806-5
- PMID
- 42288778
- PMCID
- —
- OpenAlex
- W7164676933
- Study type
- Systematic review
- Publisher
- Springer Science and Business Media LLC
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The review provides comparative treatment evidence concerning virologic outcomes, CD4+ lymphocyte counts, and reported safety outcomes in people with HIV/HBV co-infection. Its findings may support editorial understanding of the treatment-evidence literature, but the supplied abstract does not establish effectiveness in a broader population or provide implementation, access, or outcome data outside the included trials.
Structured evidence summary
Research question
The review assessed the efficacy and safety of antiretroviral regimens centered on tenofovir, lamivudine, and efavirenz for people co-infected with HIV and HBV.
Study design
This was a systematic review and network meta-analysis of 31 randomized controlled trials comparing 12 treatment interventions. Study quality was assessed with the revised ROB2 tool, and four outcome measures were analyzed.
Population and setting
The evidence comprised 2,124 participants with HIV/HBV co-infection enrolled in randomized trials identified from multiple bibliographic databases through March 2025. The abstract does not specify the countries, clinical sites, or participant demographic characteristics.
Main findings
The tenofovir plus lamivudine plus efavirenz regimen was reported to have higher HBV DNA and HIV RNA negative-conversion rates than the other evaluated regimens, and to increase CD4+ lymphocyte counts more than zidovudine plus lamivudine plus efavirenz. Reported adverse events did not differ significantly between treatment groups, while the authors noted limitations in the underlying studies and called for higher-quality research.
Public-health relevance
The review provides comparative treatment evidence concerning virologic outcomes, CD4+ lymphocyte counts, and reported safety outcomes in people with HIV/HBV co-infection. Its findings may support editorial understanding of the treatment-evidence literature, but the supplied abstract does not establish effectiveness in a broader population or provide implementation, access, or outcome data outside the included trials.
Important limitations
The authors state that limitations of the included studies reduce certainty and that further high-quality studies are needed. The supplied abstract does not describe those limitations in detail; this summary is therefore also limited to the single-article abstract and metadata and requires the original paper for decision-grade interpretation.
GIDS interpretation
The article is discoverable as treatment-focused evidence on HIV/HBV co-infection, involving antiretroviral regimen comparisons and virologic and immunologic outcomes. The supplied article does not provide a live surveillance signal, and this summary does not connect its findings to surveillance data.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 6 auditable classifier relationships to diseases, places, topics, and study design.